Next Generation ORS: Controlled Trial Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea

Last updated: August 31, 2023
Sponsor: University of Florida
Overall Status: Active - Recruiting

Phase

2/3

Condition

Lactose Intolerance

Colic

Bowel Dysfunction

Treatment

Current standard control ORS (oral rehydration solution)

Next Generation ORS (oral rehydration solution) (including placebo

Clinical Study ID

NCT05814042
IRB202202746 -N -R
1R21AI169282-01A1
  • Ages 18-60
  • All Genders

Study Summary

Diarrhea remains a leading killer of children in need of better treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult male and female patients, age between 18 and 60 years, history of acute waterydiarrhea (defined as the passage of ≥3 loose or watery stools in the past 24 hours)for less than 24 h before admission, either signs of severe dehydration and stoolpositive for Vibrio cholerae, and successful rehydration with intravenous fluidswithin the first 6 h after admission (cholera group), or signs of some dehydration andstool negative for V. cholera (non-cholera group) , and successful rehydration withintravenous or oral fluids within the first 6 h

Exclusion

Exclusion Criteria:

  • Pregnancy as determined by history of last menstrual period, bloody diarrhea, signs ofsystemic infection that needed intravenous antibiotics, or inability to rehydrate withintravenous fluid therapy in the first 6 h after admission.

Study Design

Total Participants: 396
Treatment Group(s): 2
Primary Treatment: Current standard control ORS (oral rehydration solution)
Phase: 2/3
Study Start date:
August 21, 2023
Estimated Completion Date:
December 31, 2024

Study Description

Diarrhea remains a leading killer of children in need of better treatments. Oral Rehydration Solution (ORS) is currently the only oral therapy that is recommended for children with acute diarrhea. Although it is valuable for correcting dehydration and is considered the primary reason for the substantial reduction in mortality from diarrhea in children, ORS does not have the capacity to "halt" intestinal fluid loss and thus, does not offer a rapid relief of a child's diarrhea symptom, and its use by caregivers and medical practitioners has markedly dropped (estimate use in 1/3 of cases who need it). In recognition of its limitations, continuous efforts have been made to modify the composition of ORS. However, none has targeted the central diarrhea-causing pathways and produced a satisfactory outcome in children. New therapeutic approaches and methods are needed. The proposed new ORS is based on recent discovery of the first inclusive antidiarrheal mechanism in the intestine, CaSR (calcium-sensing receptor) that targets all known diarrhea causing pathways. It works in animals. This R21 is the 1st proof-of-concept clinical study in humans and is intended to investigate its safety and efficacy. Two Specific Aims are proposed to determine new ORS safety and efficacy in patients with diarrhea. In the safety study, the investigators propose to enroll 396 diarrheal adults (198 in Intervention New ORS group and 198 in standard WHO ORS). In the efficacy study, the investigators plan to enroll 396 diarrheal adults (198 in Intervention New ORS group and 198 in standard WHO ORS, these will be same patients employed for the safety study). These diarrheal patients will be recruited from the Dhaka area in Bangladesh. At the conclusion of the study, we expect to develop a novel oral rehydrating solution that is inexpensive and practical to use in all the countries. Hypothesis: the volume output Intervention should reduce stool weight/output of diarrhea by 30%.

Connect with a study center

  • ICDDR,B Dhaka Hospital

    Dhaka, 1212
    Bangladesh

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.